Study #2024-0309
Phase I/Ib trial of TIraGolumab, AtEzolizumab, and RadScopal radiation in patients with advanced solid malignancies (TIGER)
MD Anderson Study Status
Enrolling
Treatment Agent
Tiragolumab, Atezolizumab
Description
An open-label, Phase I/Ib study investigating the safety and efficacy of tiragolumab + atezolizumab + RadScopal™ XRT in patients with metastatic solid malignancies.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Malignancies
Study phase:
Phase I
Physician name:
Ecaterina Ileana Dumbrava
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-900-1058
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.